×
Market Research Reports Categories Life Science Physical Science FAQs Contact Us Login

Ankylosing Spondylitis Market

May 2021   |    DMG00029A

The report broadly covers different types of ankylosing spondylitis based on their drug type or route of administration. Furthermore, the scope of the report also covers the impact of COVID-19 and drivers and challenges for Ankylosing Spondylitis market.

The report covers the market value for the historic year 2019, followed by the base year 2020, estimated year 2021 and forecast period from 2020 to 2026 for each drug, treatment type, molecule, route of administration, end-user, and regional markets, and the estimated values are derived from the manufacturers’ total revenues.

The report also includes a discussion of the major players across each of the regional ankylosing spondylitis markets; it explains the major market drivers of the global ankylosing spondylitis industry, current trends within the industry, major applications, and the regional dynamics of the global ankylosing spondylitis market.

The report concludes with a special focus on the vendor landscape, which includes detailed profiles of the major vendors in the global ankylosing spondylitis market.

Report Includes

  • 47 tables and 55 figures
  • An up-to-date analysis of the Global Ankylosing Spondylitis Market.
  • Analyses of the global market trends, with data from 2019, 2020, estimates for 2021, and projections of compound annual growth rates (CAGRs) through 2026.
  • Estimation of market size and revenue forecast for global ankylosing spondylitis market, and corresponding market share analysis by drug, treatment type, molecule, route of administration, end-user, and region.
  • Highlights of emerging technology trends, gaps and opportunities in the market estimating current and future demand for Ankylosing Spondylitis, identification of the companies that are best positioned to meet this demand.
  • In-depth information (facts and figures) concerning market drivers, restraints and other forces affecting the progress of this market.
  • Identification of promising new drugs, and products still in the development and testing stages, and their probability of successful commercial launch within the next five years
  • Impact of COVID-19 on the Ankylosing Spondylitis Market as compared to overall global economy.
  • Insight into the growth development strategies of major Ankylosing Spondylitis manufacturers and their key competitive landscape
  • Descriptive company profiles of the leading market participants, including AbbVie, Inc., Amgen Inc., Pfizer, Inc., Novartis AG, Eli Lilly and Company, UCB, Inc., Johnson & Johnson, Merck & Co., Inc., and others.

 

Ankylosing Spondylitis Market

Single User License: $2750

* Please allow 10 business days for delivery of this report

Enquiry Before Buying

  • Table 1 : Global Ankylosing Spondylitis Market, Through 2026
  • Table 2 : Global Ankylosing Spondylitis Market, by Drug, Through 2026
  • Table 3 : Global Ankylosing Spondylitis Market, by Treatment Type, Through 2026
  • Table 4 : Global Ankylosing Spondylitis Market, by Molecule, Through 2026
  • Table 5 : Global Ankylosing Spondylitis Market, by Route of Administration, Through 2026
  • Table 6 : Global Ankylosing Spondylitis Market, by End-User, Through 2026
  • Table 7 : Global Ankylosing Spondylitis Market, by Region, Through 2026
  • Table 8 : North America Ankylosing Spondylitis Market, by Drug, Through 2026
  • Table 9 : North America Ankylosing Spondylitis Market, by Treatment Type, Through 2026
  • Table 10 : North America Ankylosing Spondylitis Market, by Molecule, Through 2026
  • Table 11 : North America Ankylosing Spondylitis Market, by Route of Administration, Through 2026
  • Table 12 : North America Ankylosing Spondylitis Market, by End-User, Through 2026
  • Table 13 : North America Ankylosing Spondylitis Market, by Country, Through 2026
  • Table 14 : Europe Ankylosing Spondylitis Market, by Drug, Through 2026
  • Table 15 : Europe Ankylosing Spondylitis Market, by Treatment Type, Through 2026
  • Table 16 : Europe Ankylosing Spondylitis Market, by Molecule, Through 2026
  • Table 17 : Europe Ankylosing Spondylitis Market, by Route of Administration, Through 2026
  • Table 18 : Europe Ankylosing Spondylitis Market, by End-User, Through 2026
  • Table 19 : Europe Ankylosing Spondylitis Market, by Country, Through 2026
  • Table 20 : Asia-Pacific Ankylosing Spondylitis Market, by Drug, Through 2026
  • Table 21 : Asia-Pacific Ankylosing Spondylitis Market, by Treatment Type, Through 2026
  • Table 22 : Asia-Pacific Ankylosing Spondylitis Market, by Molecule, Through 2026
  • Table 23 : Asia-Pacific Ankylosing Spondylitis Market, by Route of Administration, Through 2026
  • Table 24 : Asia-Pacific Ankylosing Spondylitis Market, by End-User, Through 2026
  • Table 25 : Asia-Pacific Ankylosing Spondylitis Market, by Country, Through 2026
  • Table 26 : South America Ankylosing Spondylitis Market, by Drug, Through 2026
  • Table 27 : South America Ankylosing Spondylitis Market, by Treatment Type, Through 2026
  • Table 28 : South America Ankylosing Spondylitis Market, by Molecule, Through 2026
  • Table 29 : South America Ankylosing Spondylitis Market, by Route of Administration, Through 2026
  • Table 30 : South America Ankylosing Spondylitis Market, by End-User, Through 2026
  • Table 31 : South America Ankylosing Spondylitis Market, by Country, Through 2026
  • Table 32 : Middle East & Africa Ankylosing Spondylitis Market, by Drug, Through 2026
  • Table 33 : Middle East & Africa Ankylosing Spondylitis Market, by Treatment Type, Through 2026
  • Table 34 : Middle East & Africa Ankylosing Spondylitis Market, by Molecule, Through 2026
  • Table 35 : Middle East & Africa Ankylosing Spondylitis Market, by Route of Administration, Through 2026
  • Table 36 : Middle East & Africa Ankylosing Spondylitis Market, by End-User, Through 2026
  • Table 37 : Middle East & Africa Ankylosing Spondylitis Market, by Country, Through 2026
  • Table 38 : AbbVie, Inc.: Financial Performance, Through 2020
  • Table 39 : Amgen Inc.: Financial Performance, Through 2020
  • Table 40 : Pfizer, Inc.: Financial Performance, Through 2020
  • Table 41 : Novartis AG: Financial Performance, Through 2020
  • Table 42 : Eli Lilly and Company: Financial Performance, Through 2020
  • Table 43 : UCB, Inc.: Financial Performance, Through 2020
  • Table 44 : Johnson & Johnson: Financial Performance, Through 2020
  • Table 45 : Merck & Co., Inc.: Financial Performance, Through 2020
  • Table 46 : Boehringer Ingelheim GmbH: Financial Performance, Through 2020
  • Table 47 : F. Hoffmann-La Roche AG: Financial Performance, Through 2020
  • Figure 1 : Global Ankylosing Spondylitis Market
  • Figure 2 : Global Ankylosing Spondylitis Market, by Value, 2019-2026
  • Figure 3 : Global Ankylosing Spondylitis Market, by Value, by Drug, 2019-2026
  • Figure 4 : Global Ankylosing Spondylitis Market, by Value, by Treatment Type, 2019-2026
  • Figure 5 : Global Ankylosing Spondylitis Market, by Value, by Molecule, 2019-2026
  • Figure 6 : Global Ankylosing Spondylitis Market, by Value, by Route of Administration, 2019-2026
  • Figure 7 : Global Ankylosing Spondylitis Market, by Value, by End-User, 2019-2026
  • Figure 8 : Global Ankylosing Spondylitis Market, by Value, by Region, 2020
  • Figure 9 : Global Ankylosing Spondylitis Market, by Value, by Company, 2020
  • Figure 10 : Global Ankylosing Spondylitis Market, Product Map, 2020
  • Figure 11 : North America Ankylosing Spondylitis Market, by Value, 2019-2026
  • Figure 12 : North America Ankylosing Spondylitis Market, by Value, by Drug, 2019-2026
  • Figure 13 : North America Ankylosing Spondylitis Market, by Value, by Treatment Type, 2019-2026
  • Figure 14 : North America Ankylosing Spondylitis Market, by Value, by Molecule, 2019-2026
  • Figure 15 : North America Ankylosing Spondylitis Market, by Value, by Route of Administration, 2019-2026
  • Figure 16 : North America Ankylosing Spondylitis Market, by Value, by End-User, 2019-2026
  • Figure 17 : North America Ankylosing Spondylitis Market, by Value, by Country, 2020
  • Figure 18 : Europe Ankylosing Spondylitis Market, by Value, 2019-2026
  • Figure 19 : Europe Ankylosing Spondylitis Market, by Value, by Drug, 2019-2026
  • Figure 20 : Europe Ankylosing Spondylitis Market, by Value, by Treatment Type, 2019-2026
  • Figure 21 : Europe Ankylosing Spondylitis Market, by Value, by Molecule, 2019-2026
  • Figure 22 : Europe Ankylosing Spondylitis Market, by Value, by Route of Administration, 2019-2026
  • Figure 23 : Europe Ankylosing Spondylitis Market, by Value, by End-User, 2019-2026
  • Figure 24 : Europe Ankylosing Spondylitis Market, by Value, by Country, 2020
  • Figure 25 : Asia-Pacific Ankylosing Spondylitis Market, by Value, 2019-2026
  • Figure 26 : Asia-Pacific Ankylosing Spondylitis Market, by Value, by Drug, 2019-2026
  • Figure 27 : Asia-Pacific Ankylosing Spondylitis Market, by Value, by Treatment Type, 2019-2026
  • Figure 28 : Asia-Pacific Ankylosing Spondylitis Market, by Value, by Molecule, 2019-2026
  • Figure 29 : Asia-Pacific Ankylosing Spondylitis Market, by Value, by Route of Administration, 2019-2026
  • Figure 30 : Asia-Pacific Ankylosing Spondylitis Market, by Value, by End-User, 2019-2026
  • Figure 31 : Asia-Pacific Ankylosing Spondylitis Market, by Value, by Country, 2020
  • Figure 32 : South America Ankylosing Spondylitis Market, by Value, 2019-2026
  • Figure 33 : South America Ankylosing Spondylitis Market, by Value, by Drug, 2019-2026
  • Figure 34 : South America Ankylosing Spondylitis Market, by Value, by Treatment Type, 2019-2026
  • Figure 35 : South America Ankylosing Spondylitis Market, by Value, by Molecule, 2019-2026
  • Figure 36 : South America Ankylosing Spondylitis Market, by Value, by Route of Administration, 2019-2026
  • Figure 37 : South America Ankylosing Spondylitis Market, by Value, by End-User, 2019-2026
  • Figure 38 : South America Ankylosing Spondylitis Market, by Value, by Country, 2020
  • Figure 39 : Middle East & Africa Ankylosing Spondylitis Market, by Value, 2019-2026
  • Figure 40 : Middle East & Africa Ankylosing Spondylitis Market, by Value, by Drug, 2019-2026
  • Figure 41 : Middle East & Africa Ankylosing Spondylitis Market, by Value, by Treatment Type, 2019-2026
  • Figure 42 : Middle East & Africa Ankylosing Spondylitis Market, by Value, by Molecule, 2019-2026
  • Figure 43 : Middle East & Africa Ankylosing Spondylitis Market, by Value, by Route of Administration, 2019-2026
  • Figure 44 : Middle East & Africa Ankylosing Spondylitis Market, by Value, by End-User, 2019-2026
  • Figure 45 : Middle East & Africa Ankylosing Spondylitis Market, by Value, by Country, 2020
  • Figure 46 : AbbVie, Inc.: Revenue Share, 2020
  • Figure 47 : Amgen Inc.: Revenue Share, 2020
  • Figure 48 : Pfizer, Inc.: Revenue Share, 2020
  • Figure 49 : Novartis AG: Revenue Share, 2020
  • Figure 50 : Eli Lilly and Company: Revenue Share, 2020
  • Figure 51 : UCB, Inc.: Revenue Share, 2020
  • Figure 52 : Johnson & Johnson: Revenue Share, 2020
  • Figure 53 : Merck & Co., Inc.: Revenue Share, 2020
  • Figure 54 : Boehringer Ingelheim GmbH: Revenue Share, 2020
  • Figure 55 : F. Hoffmann-La Roche AG: Revenue Share, 2020
Ankylosing Spondylitis Market

Single User License: $5500

* Please allow 10 business days for delivery of this report

Enquiry Before Buying